Saturday 16 May 2026

Pharma & Biotech Start-up & Scale-up News

Featured

BeOne Medicines
A Nasdaq-listed oncology biotechnology company developing and commercializing cancer therapies across hematologic malignancies and solid tumors. BeOne Medicines operates a global development and commercial platform spanning North America, Europe and Asia.
Biotechnology
Biocytogen inks antibody deal with BeOne, expanding strategic ties
10 July 2025
article
IDEAYA exercises option for license on Biocytogen’s IDE034
11 November 2024

Latest Ones To Watch News

Pharmaceutical
FDA puts clinical hold on Aardvark’s IND
15 May 2026
Biotechnology
CREATE Medicines raises $122 million for in vivo CAR-T programs
15 May 2026
Biotechnology
Degron closes $40 million Series A extension
14 May 2026
More ones to watch news >
Reset all filters
Refine search
BeOne Medicines
BeOne Medicines
Nxera Pharma
Nxera Pharma
Italfarmaco
CellCentric
InflaRx
Candid Therapeutics
Axsome Therapeutics
Replay
KalVista Pharmaceuticals
Altimmune
Ajax Therapeutics
Evotec
Arcus Biosciences
Nuvalent
Neurona Therapeutics
Ewopharma
Travere Therapeutics
OriCell Therapeutics
Annovis Bio
Cue Biopharma


Today's issue

FDA greenlight for Enhertu in two new indications
Biotechnology
FDA greenlight for Enhertu in two new indications
16 May 2026
Biosimilars
FDA approves first interchangeable biosimilars to Simponi and Simponi Aria
16 May 2026
Pharmaceutical
Kelly Sanderson Schrems succeeds Steve Hopkinson as AbbVie UK GM
15 May 2026
Pharmaceutical
FDA puts clinical hold on Aardvark’s IND
15 May 2026
Pharmaceutical
Tempus AI expands collaboration with BMS
15 May 2026
Pharmaceutical
NICE backs Winrevair for PAH
15 May 2026
Biotechnology
CREATE Medicines raises $122 million for in vivo CAR-T programs
15 May 2026


Company Spotlight

A Nasdaq-listed oncology biotechnology company developing and commercializing cancer therapies across hematologic malignancies and solid tumors. BeOne Medicines operates a global development and commercial platform spanning North America, Europe and Asia.




Copyright © The Pharma Letter 2026

 |  Headless Content Management with Blaze